Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 3, 2011, Pages 242-248

  Peck Radosavljevic, Markus ^a   Boletis, John ^b   Besisik, Fatih ^c   Ferraz, Maria Lúcia ^d   Alric, Laurent ^e   Samuel, Didier ^f   Messinger, Diethelm ^g   Tietz, Andreas ^h   Cheinquer, Hugo ⁱ  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c ISTANBUL UNIVERSITY   (Turkey)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e CHU PURPAN   (France)

^f HÔPITAL PAUL BROUSSE   (France)

^g IST GmbH   (Germany)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ Hospital da Santa Casa de Misericordia de Porto Alegre   (Brazil)

Author keywords

Chronic Hepatitis C; End Stage Renal Disease; Hemodialysis; Hepatitis C Virus; Peginterferon; Sustained Virologic Response

Indexed keywords

PEGINTERFERON ALPHA2A; VIRUS RNA;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; AUTOINFLAMMATORY DISEASE; BRAIN HEMORRHAGE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; GRAND MAL SEIZURE; HEADACHE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; HYPOTHYROIDISM; INSOMNIA; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; NEUTROPHIL COUNT; OPEN STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 79951699393     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.10.018     Document Type: Article

References (34)

1. Dienstag J.L., McHutchison J.G. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006, 130:231-264.
2. Fabrizi F., Poordad F.F., Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002, 36:3-10.
3. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556-562.
4. Alter M.J., Lyerla R.L., Tokars J.I., et al. Recommendations for preventing transmission of infections among chronic hemodialysis patients. Morb Mort Weekly Rep 2001, 50:42.
5. Finelli L., Miller J.T., Tokars J.I., et al. National Surveillance of Dialysis-Associated Diseases in the United States. Semin Dial 2005, 18:52-61. 2002.
6. Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2008, 48:1690-1699.
7. Carneiro M.A., Teles S.A., Lampe E., et al. Molecular and epidemiological study on nosocomial transmission of HCV in hemodialysis patients in Brazil. J Med Virol 2007, 79:1325-1333.
8. Olmer M., Bouchouareb D., Zandotti C., et al. Transmission of the hepatitis C virus in an hemodialysis unit: evidence for nosocomial infection. Clin Nephrol 1997, 47:263-270.
9. Sampietro M., Badalamenti S., Salvadori S., et al. High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit: evidence for nosocomial transmission of HCV. Kidney Int 1995, 47:911-917.
10. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008, 73:S1-S99. Kidney Disease: Improving Global Outcomes (KDIGO).
11. Fabrizi F., Martin P., Dixit V., et al. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005, 5:1452-1461.
12. Butt A.A., Skanderson M., McGinnis K.A., et al. Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis. J Viral Hepat 2007, 14:688-696.
13. Strader D.B., Wright T., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
14. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
15. Fabrizi F., Dulai G., Dixit V., et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003, 18:1071-1081.
16. Izopet J., Rostaing L., Moussion F., et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997, 176:1614-1617.
17. Russo M.W., Ghalib R., Sigal S., et al. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006, 21:437-443.
18. Pockros P.J., Carithers R., Desmond P., et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004, 99:1298-1305.
19. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
20. Heathcote E.J., Shiffman M.L., Cooksley W.G., et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673-1680.
21. Zeuzem S., Feinman S.V., Rasenack J., et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343:1666-1672.
22. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
23. Fabrizi F., Dixit V., Messa P., et al. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008, 15:79-88.
24. Gordon C.E., Uhlig K., Lau J., et al. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 2008, 51:263-277.
25. Sikole A., Dzekova P., Selja N., et al. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy. Ren Fail 2007, 29:961-966.
26. Ferenci P., Fried M.W., Shiffman M.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005, 43:425-433.
27. Hadziyannis S.J., Sette H., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
28. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
29. Shiffman M.L., Suter F., Bacon B.R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007, 357:124-134.
30. Covic A., Maftei I.D., Mardare N.G., et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 2006, 19:794-801.
31. Yoshino M., Kuhlmann M.K., Kotanko P., et al. International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 2006, 17:3510-3519.
32. Rendina M., Schena A., Castellaneta N.M., et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007, 46:768-774.
33. Wang K., Lawal A.A., Majchrowicz M., et al. Pharmacokinetics (PK) of ribavirin (RBV) in patients with renal impairment or end-stage disease (ESRD) and chronic hepatitis C (CHC) during treatment with peginterferon alfa-2a (PEGASYS®) and RBV (COPEGUS®). Hepatology 2008, 48:1142.
34. Bruchfeld A., Lindahl K., Reichard O., et al. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006, 13:316-321.